Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage primarily focuses on early stage companies with impending FDA and/or clinical trial catalysts. Our coverage may also include mid-to-large cap biopharma companies where there exists specific catalysts. Where appropriate, our recommended trade and investment ideas incorporate the use of simple to more complex option strategies. Our coverage universe is continuously updated and includes research and trade/investment ideas for the Top 10 up-and-coming catalysts that represent the best opportunities for traders and investors. The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Liu Jiao is a small-business and personal-finance writer. Studied economics in college, she has a real fascination with the markets and has been investing in the stock market for five years.
She is willing to share opinions with other investors for making better, smarter investing choices. She is good at writing many types of personal finance as well as business finance, including saving, stock investments, paying off debt and retirement.
I am a self-taught investor. My initial interest in stocks and the market began as a Sophomore in college. Since then I have been learning and reading everything I could get my hands on to the point where I am now comfortable and profitable in various trading styles. Given my career as a financial professional, I have also been able to learn how private company sales are made and how other traders on Wall Street trade. I currently am a value investor and also invest / trade short-term momentum, special situations, and growth stocks. I have recently started trading currency.